Clinical Takeaway
A phase 3 randomized controlled trial enrolled 820 adults with chronic low back pain to evaluate VER-01, a full-spectrum cannabis extract, against placebo over a 12-week double-blind period with up to one year of follow-up. The trial design includes both an open-label extension and a randomized withdrawal phase, providing an unusually rigorous look at both sustained benefit and what happens when treatment stops. This represents one of the most methodologically robust clinical investigations of a cannabis-based medicine for one of the world’s most prevalent pain conditions.
#2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
What This Study Teaches Us
A full-spectrum cannabis extract (VER-01) reduced chronic low back pain by about 0.6 points on a 10-point scale more than placebo over 12 weeks, with further improvement sustained over longer follow-up. The effect was modest but statistically significant, and neuropathic pain symptoms also improved more with the active treatment.
Why This Matters Clinically
Chronic low back pain is one of the most common causes of disability and opioid prescribing. A phase 3 trial showing benefit in a large population (820 participants) suggests cannabis extracts may have a role in the treatment arsenal, though the magnitude of benefit is small and needs honest discussion with patients about expectations.
Study Snapshot
| Study Design | Multicenter randomized placebo-controlled phase 3 trial with 12-week double-blind phase, 6-month open-label extension, and randomized withdrawal phase |
| Population | 820 adults with chronic low back pain (394 VER-01, 426 placebo). Demographics not specified in abstract. |
| Intervention | VER-01, a full-spectrum cannabis extract from strain DKJ127. Specific dose and dosing schedule not specified in abstract. |
| Primary Outcome | Change in pain intensity measured on numeric rating scale (NRS, 0-10) over 12 weeks |
| Key Result | VER-01 reduced pain by 1.9 NRS points; placebo reduced pain by 1.3 NRS points; difference of 0.6 points favoring active treatment (P < 0.001). Neuropathic pain subscore improved 7.3 points more with VER-01 (P = 0.017). |
Where This Paper Deserves Skepticism
The primary endpoint difference of 0.6 NRS points is statistically significant but clinically small, raising questions about whether this magnitude matters to patients in real practice. The abstract does not specify dosing, adverse event details (stating only that 83.3% of VER-01 recipients had AEs versus an incomplete comparator percentage), participant demographics, or funding source, all of which affect interpretation. The randomized withdrawal phase (phase D) failed to show superiority, suggesting discontinuation may not be clearly worse than placebo, which weakens the case for sustained benefit. The abstract is sparse on key methodologic details needed for full appraisal.
Dr. Caplan’s Take
This is a competently designed phase 3 trial that demonstrates statistical benefit for a cannabis extract in chronic low back pain, but I’d caution against overinterpreting the magnitude. A 0.6-point difference on a 10-point pain scale is real but modest, and whether patients feel that difference in their function or quality of life isn’t clear from this abstract. The higher adverse event rate with active treatment (even if mostly mild) needs to be weighed against that modest benefit in individual conversations. I’d want to see the full paper to understand dosing, head-to-head comparisons with standard care, and which patient subgroups benefited most before changing my prescribing patterns significantly.
Clinical Bottom Line
This phase 3 trial shows VER-01 produces modest pain reduction in chronic low back pain compared to placebo, but the clinical significance of a 0.6-point improvement and the higher adverse event burden warrant careful patient selection and expectation-setting. Full-paper review is needed before integrating this into routine practice.
| |
Have thoughts on this? Share it:
